Cost-savings for the NHS

Find out how much your locality could save with STADA UK’s respiratory portfolio, compared to your current usage by requesting a tailored cost savings report.

Request report

Request meeting

At STADA UK, we go beyond carbon offsetting

We are dedicated to measuring and reducing carbon emissions across our respiratory medicines portfolio on an ongoing basis, aiming to achieve to become net-zero by 2045.

References

  1. Proxor® Prescribing Information. Accessed: November 2026.
  2. Trokide® Prescribing Information. Accessed: November 2026.
  3. Fixkoh® Prescribing Information. Accessed: November 2026.

The information in this website is intended solely for UK Healthcare Professionals and contains promotional information.

I confirm I am a UK Healthcare Professional

UK Patients – If you have been prescribed one of our products by a UK healthcare professional, you can visit the dedicated patient sites for more information: Trokide® | Proxor® | Fixkoh®

Other visitors – Please visit our main web site.

UK-MULT-307(1) | July 2025

The information in this website is intended solely for UK Healthcare Professionals and contains promotional information.

I confirm I am a UK Healthcare Professional

UK Patients – If you have been prescribed one of our products by a UK healthcare professional, you can visit the dedicated patient sites for more information: Trokide® | Proxor® | Fixkoh®

Other visitors – Please visit our main web site.

UK-MULT-307(1) | July 2025

The information in this website is intended solely for UK Healthcare Professionals and contains promotional information.

I confirm I am a UK Healthcare Professional

UK Patients – If you have been prescribed one of our products by a UK healthcare professional, you can visit the dedicated patient sites for more information: Trokide® | Proxor® | Fixkoh®

Other visitors – Please visit our main web site.

UK-MULT-307(1) | July 2025

The information in this website is intended solely for UK Healthcare Professionals and contains promotional information.

I confirm I am a UK Healthcare Professional

UK Patients – If you have been prescribed one of our products by a UK healthcare professional, you can visit the dedicated patient sites for more information: Trokide® | Proxor® | Fixkoh®

Other visitors – Please visit our main web site.

UK-MULT-307(1) | July 2025

Proxor® (beclometasone/formoterol) indications1

For use in adults only.

Asthma

Proxor® 100/6 and 200/6: Regular treatment of asthma where use of a combination product is appropriate: Patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled rapid-acting β2-agonist; Patients already adequately controlled on both inhaled corticosteroids and long-acting β2-agonists.

Chronic Obstructive Pulmonary Disease (COPD)

Proxor® 100/6: Symptomatic treatment of severe COPD (FEV1 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. Proxor® 100/6 is licensed for Maintenance and Reliever Therapy (MART) in asthma.

Trokide® (tiotropium bromide) indications2

Trokide Vertical-Haler® is indicated as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).

Fixkoh® (salmeterol/fluticasone) indications3

Fixkoh Airmaster® is indicated in adults and adolescents 12 years of age and older.

Asthma

In the regular treatment of asthma where use of a combination product (long-acting β2 agonist and inhaled corticosteroid is appropriate. In patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β2 agonist, or, patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist. Note: Fixkoh Airmaster® 50 microgram/100 micrograms is not appropriate in adults and children with severe asthma.

Chronic Obstructive Pulmonary Disease (COPD)

For the symptomatic treatment of patients with COPD, with a FEV1 < 60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.